# Karyopharm Therapeutics Inc.: overview KPTI · Nasdaq · CIK 1503802 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/kpti.md) · [Financials](/companies/kpti/financials.md) · [Filings](/companies/kpti/filings.md) · [Insiders](/companies/kpti/insiders.md) Latest reported revenue: [$33.4m](/filings/0001193125-26-347906.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-347906). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [38.8](/filings/0001193125-25-261667.md) | [30.5 d](/filings/0001193125-26-049397.md) | [30.0](/filings/0001193125-26-222827.md) | [37.9](/filings/0001193125-26-347906.md) | [44.0](/filings/0001193125-25-261667.md) | [34.1 d](/filings/0001193125-26-049397.md) | [35.1](/filings/0001193125-26-222827.md) | [33.4](/filings/0001193125-26-347906.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(67.8%)](/filings/0001193125-25-261667.md) | [(102.4%) d](/filings/0001193125-26-049397.md) | [(110.8%)](/filings/0001193125-26-222827.md) | [(64.3%)](/filings/0001193125-26-347906.md) | [(34.6%)](/filings/0001193125-25-261667.md) | [(52.4%) d](/filings/0001193125-26-049397.md) | [(76.3%)](/filings/0001193125-26-222827.md) | [(67.4%)](/filings/0001193125-26-347906.md) | | Net margin | % | [(82.7%)](/filings/0001193125-25-261667.md) | [(100.8%) d](/filings/0001193125-26-049397.md) | [(78.2%)](/filings/0001193125-26-222827.md) | [(98.2%)](/filings/0001193125-26-347906.md) | [(75.2%)](/filings/0001193125-25-261667.md) | [(299.9%) d](/filings/0001193125-26-049397.md) | [(63.9%)](/filings/0001193125-26-222827.md) | [(200.5%)](/filings/0001193125-26-347906.md) | | Diluted EPS | $ per share | [(3.85)](/filings/0001193125-25-261667.md) | not reported | [(2.77)](/filings/0001193125-26-222827.md) | [(4.32)](/filings/0001193125-26-347906.md) | [(3.82)](/filings/0001193125-25-261667.md) | not reported | [(1.24)](/filings/0001193125-26-222827.md) | [(2.32)](/filings/0001193125-26-347906.md) | | Free cash flow | $m | [(19.5) d](/filings/0001193125-25-261667.md) | [(25.9) d](/filings/0001193125-26-049397.md) | [(39.0)](/filings/0001193125-26-222827.md) | [(18.7) d](/filings/0001193125-26-347906.md) | [(5.9) d](/filings/0001193125-25-261667.md) | [(11.8) d](/filings/0001193125-26-049397.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [210](/filings/0000950170-24-022650.md) | [157](/filings/0000950170-25-022765.md) | [146](/filings/0001193125-26-049397.md) | [145](/filings/0001193125-26-049397.md) | [146](/filings/0001193125-26-049397.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(46.8%)](/filings/0000950170-24-022650.md) | [(90.5%)](/filings/0000950170-25-022765.md) | [(88.7%)](/filings/0001193125-26-049397.md) | [(82.2%)](/filings/0001193125-26-049397.md) | [(62.1%)](/filings/0001193125-26-049397.md) | | Net margin | % | [(59.1%)](/filings/0000950170-24-022650.md) | [(105.2%)](/filings/0000950170-25-022765.md) | [(98.0%)](/filings/0001193125-26-049397.md) | [(52.6%)](/filings/0001193125-26-049397.md) | [(134.2%)](/filings/0001193125-26-049397.md) | | Diluted EPS | $ per share | [(1.65)](/filings/0000950170-24-022650.md) | [(2.02)](/filings/0000950170-25-022765.md) | [(18.79)](/filings/0001193125-26-049397.md) | [(14.00)](/filings/0001193125-26-049397.md) | [(17.93)](/filings/0001193125-26-049397.md) | | Free cash flow | $m | [(107)](/filings/0000950170-24-022650.md) | [(150)](/filings/0000950170-25-022765.md) | [(92.7)](/filings/0001193125-26-049397.md) | [(128)](/filings/0001193125-26-049397.md) | [(75.4)](/filings/0001193125-26-049397.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/kpti/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $18.7m | 1,917,354 | | Unchanged | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $14.9m | 1,521,322 | | Reduced −285,000 | | [ACORN CAPITAL ADVISORS, LLC](/funds/2054410.md) | 2026-06-30 | $14.8m | 1,518,113 | | Added +1,230,287 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $13.9m | 1,424,658 | | Added +477,079 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $13.9m | 1,418,799 | | Added +1,173,900 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $9.4m | 958,979 | | Added +219,234 | | [Catalio Capital Management, LP](/funds/1958125.md) | 2026-06-30 | $9.2m | 940,855 | | Added +43,146 | | [Avidity Partners Management LP](/funds/1791827.md) | 2026-06-30 | $9.0m | 924,487 | | Added +460,746 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $6.8m | 695,264 | | Added +544,032 | | [Kalehua Capital Management LLC](/funds/2106181.md) | 2026-06-30 | $6.7m | 685,644 | | New +685,644 | ## Recent filings [All 1,130 filings](/companies/kpti/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 16:15 ET | [8-K](/filings/0001193125-26-428938.md) | 8.01 Other events | 0001193125-26-428938 | | 2026-10-14 | 07:30 ET | [8-K](/filings/0001193125-26-421025.md) | 8.01 Other events | 0001193125-26-421025 | | 2026-09-18 | 16:05 ET | [8-K](/filings/0001193125-26-395517.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-395517 | | 2026-09-11 | 07:45 ET | [8-K](/filings/0001193125-26-388621.md) | 1.01 Entry into a material agreement; 2.04 Item not in the standard list; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-388621 | | 2026-08-31 | 08:08 ET | [8-K](/filings/0001193125-26-375495.md) | 8.01 Other events | 0001193125-26-375495 | | 2026-08-13 | 07:40 ET | [10-Q](/filings/0001193125-26-347906.md) | Quarterly report, period 2026-06-30 | 0001193125-26-347906 | | 2026-08-13 | 07:37 ET | [8-K](/filings/0001193125-26-347897.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-347897 | | 2026-07-31 | 08:30 ET | [8-K](/filings/0001193125-26-326995.md) | 8.01 Other events | 0001193125-26-326995 | | 2026-07-17 | 17:01 ET | [8-K](/filings/0001193125-26-307964.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-307964 | | 2026-05-28 | 16:15 ET | [8-K](/filings/0001503802-26-000027.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001503802-26-000027 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-049397.md), filed Feb 13, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9546ad2d-b22e-4d99-8c55-7e58009b7191) ## About the filer - CIK: 1503802 - Tickers: KPTI - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 04:32 ET. No prices; not investment advice.